Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
Yeh R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, Min R, Park S, Brockway JP, Bromberg JF, Zhi WI, Robson ME, Sanford R, Modi S, Agnew BJ, Lyashchenko SK, Lewis JS, Ulaner GA, Zeglis BM. Yeh R, et al. Among authors: o donoghue ja. J Nucl Med. 2024 Mar 1;65(3):386-393. doi: 10.2967/jnumed.123.266392. J Nucl Med. 2024. PMID: 38272704 Free PMC article.
A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.
Pandit-Taskar N, O'Donoghue JA, Chetty D, Max S, Wanik D, Ilovich O, Russell M, Nyima T, Divgi CR, Yu M, Morris MJ. Pandit-Taskar N, et al. Among authors: o donoghue ja. J Nucl Med. 2024 May 23:jnumed.124.267416. doi: 10.2967/jnumed.124.267416. Online ahead of print. J Nucl Med. 2024. PMID: 38782459
Lesion Dosimetry for [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer.
Grkovski M, O'Donoghue JA, Imber BS, Andl G, Tu C, Lafontaine D, Schwartz J, Thor M, Zelefsky MJ, Humm JL, Bodei L. Grkovski M, et al. Among authors: o donoghue ja. J Nucl Med. 2023 Nov;64(11):1779-1787. doi: 10.2967/jnumed.123.265763. Epub 2023 Aug 31. J Nucl Med. 2023. PMID: 37652541 Free PMC article.
Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89Zr-Trastuzumab PET: A Pilot Study.
Lumish MA, Maron SB, Paroder V, Chou JF, Capanu M, Philemond S, O'Donoghue JA, Schöder H, Lewis JS, Lyashchenko SK, Pandit-Taskar N, Janjigian YY. Lumish MA, et al. Among authors: o donoghue ja. J Nucl Med. 2023 May;64(5):724-730. doi: 10.2967/jnumed.122.264470. Epub 2022 Nov 23. J Nucl Med. 2023. PMID: 36418168 Free PMC article.
[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma.
Krebs S, Grommes C, McDevitt MR, Carlin SD, O'Donoghue JA, Graham MS, Young RJ, Schöder H, Gutin PH, Bander NH, Osborne JR. Krebs S, et al. Among authors: o donoghue ja. Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):783-785. doi: 10.1007/s00259-021-05543-5. Epub 2021 Sep 8. Eur J Nucl Med Mol Imaging. 2022. PMID: 34498111 No abstract available.
99 results